Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia

Summary

The primary goal of this study is to evaluate the safety and efficacy of two different dosing regimens of an investigational drug called Avexitide in treating low blood sugar in patients with Acquired Hyperinsulinemic Hypoglycemia.

Timeline

Start

2021-06-21

Primary completion

2022-06-30

Completion

2022-06-30

Outcome

Met primary endpoint

registry analysis (other test); Avexitide 45 mg Twice Daily; p = 0.0028; Mixed effects model NCT04652479 ↗

registry analysis (other test); Avexitide 90 mg Once Daily; p = 0.0005; Mixed effects model NCT04652479 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avexitide	Peptide	45 mg	—
Subject	Avexitide	Peptide	90 mg	—

Indications